DekaBank Deutsche Girozentrale
ESPR

DekaBank Deutsche Girozentrale’s Esperion Therapeutics ESPR Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$123K – 1436
2021
Q3 		$123K Hold
10,000
– – ﹤0.01% 1282
2021
Q2 		$208K Hold
10,000
– – ﹤0.01% 1213
2021
Q1 		$271K Hold
10,000
– – ﹤0.01% 1135
2020
Q4 		$269K Hold
10,000
– – ﹤0.01% 1138
2020
Q3 		$370K Buy
+10,000
New +$396K ﹤0.01% 977

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale's ESPR Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 10,000 shares — an estimated $123K sold.

DekaBank Deutsche Girozentrale first reported a position in ESPR in Q3 2020 and held it in 5 quarters. The position peaked at $370K in Q3 2020. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

  • DekaBank Deutsche Girozentrale reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 10,000 Esperion Therapeutics shares in Q4 2021, an estimated $123K.
  • DekaBank Deutsche Girozentrale first reported a position in Esperion Therapeutics in Q3 2020 and held it in 5 quarters.
  • DekaBank Deutsche Girozentrale's Esperion Therapeutics position peaked at $370K in Q3 2020.
  • 133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.